Molecular hydrogen protects against ischemia-reperfusion injury in a mouse fatty liver model via regulating HO-1 and Sirt1 expression.
Shaowei Li, Masayuki Fujino, Naotsugu Ichimaru, Ryosuke Kurokawa, Shinichi Hirano, Lisha Mou, Shiro Takahara, Terumi Takahara, Xiao-Kang Li · Scientific reports · 2018
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In contrast, H₂ treatment significantly suppressed the signs of I/R injury in fatty liver. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in mice. In contrast, H₂ treatment significantly suppressed the signs of I/R injury in fatty liver.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
The mice were randomly divided into 3 groups (n = 10, each group), as follows: (1) MCDHF group:fatty liver mice with sham operation. (2) MCDHF I/R group: fatty liver mice pre-treated with saline before I/R, then sacrificed after 3 hr reperfusion; 1 ml saline spreaded on the liver after clipping hepatic portal vein with a microvascular clamp for ischemia; (3) MCDHF I/R + HS group: fatty liver mice treated with hydrogen saline before I/R, then sacrificed after 3 hr reperfusion. The primary hepatocytes bearing fat droplets isolated from steatotic liver were randomly divided into four groups as follows: Group 1: Control group, fatty primary hepatocytes. Group 2: Hydrogen gas group, fatty primary hepatocytes treated 10 hr with hydrogen gas; Group 3: Hypoxia/reoxygenation group, fatty primary hepatocytes subjected to 4 hr of hypoxia and 6 hr of reoxygenation; Group 4: Hypoxia/reoxygenation + hydrogen gas group, fatty primary hepatocytes treated with hydrogen gas plus hypoxia/reoxygenation. In contrast, H₂ treatment significantly suppressed the signs of I/R injury in fatty liver. The authors concluded that in the present study, treatment with molecular hydrogen resulted in significantly increased HO-1 expression both in liver homogenate and KCs isolated from fatty liver that underwent I/R injury (Figs 2 and 3 ). Apoptosis-related proteins and components of the signaling pathway were analyzed after treatment with hydrogen gas.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment.
Limitations and Safety
Safety information: Taken togather, treatment with H₂ saline may have a protective effect and safe therapeutic activity during I/R events, such as in liver transplantation with fatty liver.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.